Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'

被引：5
|
作者：
Banday, Aaqib Zaffar [1 ]
Jindal, Ankur Kumar [1 ]
Singh, Surjit [1 ]
机构：
[1] Post Grad Inst Med Educ & Res, Dept Pediat, Allergy Immunol Unit, Chandigarh, India
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷 / 05期
关键词：
autoimmunity; immune system diseases; inflammation; therapeutics; RUXOLITINIB; EFFICACY;
D O I：
10.1136/annrheumdis-2021-219890
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review
    Kraev, Krasimir
    Geneva-Popova, Mariela Gencheva
    Hristov, Bozhidar Krasimirov
    Uchikov, Petar Angelov
    Belova-Popova, Stanislava Dimitrova
    Kraeva, Maria Ilieva
    Basheva-Kraeva, Yordanka Mincheva
    Stoyanova, Nina Staneva
    Mitkova-Hristova, Vesela Todorova
    Koleva-Ivanova, Maria Stoyanova
    Taneva, Daniela Ivova
    Ivanov, Atanas Slavchev
    LIFE-BASEL, 2023, 13 (12):
  • [2] Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
    Roskoski, Robert, Jr.
    PHARMACOLOGICAL RESEARCH, 2016, 111 : 784 - 803
  • [3] Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital
    Huaranga, Marco Aurelio Ramirez
    Pascual, Luis Angel Calvo
    Sanchez, David Velasco
    Lopez, Lourdes Martin de la Sierra
    Rodriguez, Laura Jimenez
    Mora, Alberto Lopez Menchero
    Corredor, David Castro
    Penas, Marina Gonzalez
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [4] Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review
    Challoumas, Dimitris
    Simpson, Cameron
    Arnold, Matthew
    Mease, Philip
    Moots, Robert
    Ndosi, Mwidimi
    Locher, Zoe Rutter
    AUTOIMMUNITY REVIEWS, 2025, 24 (03)
  • [5] Potential cardiovascular implications of Janus kinase inhibitors in immune mediated diseases
    Mehta, Nehal N.
    CARDIOVASCULAR RESEARCH, 2018, 114 (11) : E81 - E83
  • [6] Adiponectin in inflammatory and immune-mediated diseases
    Fantuzzi, Giamila
    CYTOKINE, 2013, 64 (01) : 1 - 10
  • [7] Janus Kinase Inhibitors in inflammatory Bowel Diseases
    Stange, Eduard F.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (07): : 798 - 799
  • [8] Genetics of immune-mediated inflammatory diseases
    David, T.
    Ling, S. F.
    Barton, A.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 193 (01) : 3 - 12
  • [9] The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
    Damsky, William
    Peterson, Danielle
    Ramseier, Julie
    Al-Bawardy, Badr
    Chun, Hyung
    Proctor, Deborah
    Strand, Vibeke
    Flavell, Richard A.
    King, Brett
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (03) : 814 - 826
  • [10] Chilblains in immune-mediated inflammatory diseases: a review
    Dubey, Shirish
    Joshi, Nilay
    Stevenson, Olivia
    Gordon, Caroline
    Reynolds, John A.
    RHEUMATOLOGY, 2022, 61 (12) : 4631 - 4642
12345